<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01015937</url>
  </required_header>
  <id_info>
    <org_study_id>3997</org_study_id>
    <nct_id>NCT01015937</nct_id>
  </id_info>
  <brief_title>Effect of Turmeric on Diabetic Nephropathy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaheed Faghihi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shaheed Faghihi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether turmeric is effective in improvement of
      diabetic nephropathy and in decrease in the amount of proteinuria and cytokine levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic nephropathy is leading cause of ESRF that many therapy recommended for it. In this
      study, we investigate effect of turmeric on diabetic nephropathy, thus we selected diabetic
      nephropathy patients and divided them into 2 groups. One group received turmeric + ACE
      inhibitor + Angiotensin II receptor blocker (ARB) and the second group received only ACE
      inhibitor + ARB.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <condition>Proteinuria</condition>
  <arm_group>
    <arm_group_label>Turmeric</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>diabetic nephropathy patient
more than 300 mg/proteinuria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACE inhibitor + ATI blocker</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>diabetic nephropathy
more than 300 mg/day proteinuria</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Turmeric extract</intervention_name>
    <description>turmeric 500 mg TID for 45 days</description>
    <arm_group_label>Turmeric</arm_group_label>
    <arm_group_label>ACE inhibitor + ATI blocker</arm_group_label>
    <other_name>turmeric</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angiotensin-converting enzyme (ACE) inhibitor + Angiotensin-II type 1 receptor (ATI) blocker</intervention_name>
    <description>maximum dosage as patient tolerated for 45 days</description>
    <arm_group_label>ACE inhibitor + ATI blocker</arm_group_label>
    <other_name>enalapril</other_name>
    <other_name>losartan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diabetic nephropathy

          -  more than 300 mg proteinuria/day

          -  age more than 18 years old

        Exclusion Criteria:

          -  DM type 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>maryam pakfetrat, assistant professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shiraz nephro-urology research center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinic</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <zip>098</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://www.pubmed.com</url>
  </link>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2009</study_first_submitted>
  <study_first_submitted_qc>November 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2009</study_first_posted>
  <last_update_submitted>November 17, 2009</last_update_submitted>
  <last_update_submitted_qc>November 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Office of Vice Chancellor for research in Shiraz UMS</name_title>
    <organization>Shiraz University of Medical Science</organization>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>nephropathy</keyword>
  <keyword>turmeric</keyword>
  <keyword>serum IL8</keyword>
  <keyword>serum TGFb</keyword>
  <keyword>serumINF</keyword>
  <keyword>urinary IL8</keyword>
  <keyword>urine TGFb</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiotensin II</mesh_term>
    <mesh_term>Angiotensinogen</mesh_term>
    <mesh_term>Turmeric extract</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

